Sulfonylguanidine Derivatives as Potential Antimelanoma Agents.
Antineoplastic Agents
/ chemical synthesis
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Dose-Response Relationship, Drug
Drug Screening Assays, Antitumor
Guanidine
/ analogs & derivatives
Humans
Hydrogen-Ion Concentration
Melanoma
/ drug therapy
Molecular Docking Simulation
Molecular Structure
Skin Neoplasms
/ drug therapy
Structure-Activity Relationship
anticancer agents
aryl sulfonyl guanidine
benzothiazole/benzimidazole drugs
deamidination
melanoma
sulfoguanidines
Journal
ChemMedChem
ISSN: 1860-7187
Titre abrégé: ChemMedChem
Pays: Germany
ID NLM: 101259013
Informations de publication
Date de publication:
03 07 2020
03 07 2020
Historique:
received:
07
04
2020
revised:
26
04
2020
pubmed:
30
4
2020
medline:
16
6
2021
entrez:
30
4
2020
Statut:
ppublish
Résumé
Sulfonylguanidines are interesting bioactive compounds with a broad range of applications in the treatment of different pathologies. 2-Aminobenzazole-based structures are well employed in the development of new anticancer drugs. Two series of novel N-benzazol-2-yl-N'-sulfonyl guanidine derivatives were synthesized with the sulfonylguanidine in either an extra- or intracyclic frame. They were evaluated for their antiproliferative activity against malignant melanoma tumor cells, thus allowing structure-activity relationships to be defined. Additionally, NCI-60 screening was performed for the best analogue to study its efficiency against a panel of other cancer cell lines. The stability profile of this promising compound was then validated. During the synthetic process, an unexpected new deamidination of the sulfonylguanidine towards sulfonamide function was also identified.
Identifiants
pubmed: 32347004
doi: 10.1002/cmdc.202000218
doi:
Substances chimiques
Antineoplastic Agents
0
sulfonylguanidine
0
Guanidine
JU58VJ6Y3B
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1113-1117Informations de copyright
© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
Références
W. Loop, H. Baganz, F. W. Kohlmann, H. Schultze, N<1>-[p-Amino-Benzene-Sulfonyl]-N<3>-[4,5-Dimethyloxazolyl-(2)]-Guanidino, GB1185139A, UK, 1970.
K. S. Kalyan, M. V. Saurabh, P. Naru, M. A. Mathrusri, Lett. Drug Des. Discovery 2011, 8, 774-777.
C. T. Supuran, A. Scozzafava, F. Briganti, B. W. Clare, J. Med. Chem. 2000, 43, 1793-1806.
R. M. Scarborough, H.-M. Jantzen, W. Huang, D. Sedlock, C. Marlowe, K. Kane-Maguire, Platelet ADP Receptor Inhibitors, US20020077486 A1 (Ed.: P. P. Inc), US, 2002;
R. M. Scarborough, H.-M. Jantzen, W. Huang, D. M. Sedlock, C. K. Marlowe, Platelet ADP Receptor Inhibitors, WO2001057037 A1, 2000.
U. Ramesh, G. Look, R. Singh, S. Issakani, Ubiquitin Ligase Inhibitors, US20050009871A1, USA, 2005.
F. Saczewski, Ł. Balewski, Expert Opin. Ther. Pat. 2009, 19, 1417-1448;
F. Sączewski, Ł. Balewski, Expert Opin. Ther. Pat. 2013, 23, 965-995;
J. Sławiński, Z. Brzozowski, Eur. J. Med. Chem. 2006, 41, 1180-1189.
W. O. Foye, S. H. An, T. J. Maher, J. Pharm. Sci. 1984, 73, 1168-1170.
C. Di Giovanni, R. Ettari, S. Sarno, A. Rotondo, A. Bitto, F. Squadrito, D. Altavilla, T. Schirmeister, E. Novellino, S. Grasso, M. Zappalà, A. Lavecchia, Eur. J. Med. Chem. 2016, 121, 578-591.
J. Sławiński, Pol. J. Chem. 2002, 76, 937-944.
B. Żołnowska, J. Sławiński, A. Pogorzelska, J. Chojnacki, D. Vullo, C. T. Supuran, Eur. J. Med. Chem. 2014, 71, 135-147.
S. Ashwell, T. Gero, S. Ionnidis, J. Janetka, P. Lyne, M. Su, D. Toader, D. Yu, Y. Yu, Thiophene Derivatives as CHK 1 Inihibitors, WO2005066163 A2, 2005.
M. N. Noolvi, H. M. Patel, M. Kaur, Eur. J. Med. Chem. 2012, 54, 447-462;
H. M. Refaat, Eur. J. Med. Chem. 2010, 45, 2949-2956.
M. Dufies, O. Grytsai, C. Ronco, O. Camara, D. Ambrosetti, A. Hagege, J. Parola, L. Mateo, M. Ayrault, S. Giuliano, R. Grépin, N. Lagarde, M. Montes, P. Auberger, L. Demange, R. Benhida, G. Pagès, Theranostics 2019, 9, 5332-5346.
S. M. Verma, M. Dadheech, R. P. Meena, PharmaSciTech 2012, 1, 30-35.
A. Millet, A. R. Martin, C. Ronco, S. Rocchi, R. Benhida, Med. Res. Rev. 2017, 37, 98-148;
A. Millet, M. Plaisant, C. Ronco, M. Cerezo, P. Abbe, E. Jaune, E. Cavazza, S. Rocchi, R. Benhida, J. Med. Chem. 2016, 59, 8276-8292;
B. Domingues, J. M. Lopes, P. Soares, H. Pópulo, ImmunoTargets and Therapy 2018, 7, 35.
A. Dolzhenko, W.-K. Chui, A. Dolzhenko, Synthesis 2006, 2006, 597-602.
O. Grytsai, T. Druzhenko, L. Demange, C. Ronco, R. Benhida, Tetrahedron Lett. 2018, 59, 1642-1645.
A. V. Dolzhenko, W.-K. Chui, J. Heterocycl. Chem. 2006, 43, 95-100.
A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo, M. Boyd, JNCI J. Natl. Cancer Inst. 1991, 83, 757-766;
J. N. Weinstein, T. G. Myers, P. M. Connor, S. H. Friend, A. J. Fornace, K. W. Kohn, T. Fojo, S. E. Bates, L. V. Rubinstein, N. L. Anderson, J. K. Buolamwini, W. W. van Osdol, A. P. Monks, D. A. Scudiero, E. A. Sausville, D. W. Zaharevitz, B. Bunow, V. N. Viswanadhan, G. S. Johnson, R. E. Wittes, K. D. Paull, Science 1997, 275, 343.